Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Mitchell Denker"'
Autor:
Jeffrey J. Wallin, Johanna C. Bendell, Roel Funke, Mario Sznol, Konstanty Korski, Suzanne Jones, Genevive Hernandez, James Mier, Xian He, F. Stephen Hodi, Mitchell Denker, Vincent Leveque, Marta Cañamero, Galina Babitski, Hartmut Koeppen, James Ziai, Neeraj Sharma, Fabien Gaire, Daniel S. Chen, Daniel Waterkamp, Priti S. Hegde, David F. McDermott
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-8 (2016)
Cancer immunotherapy can be used in combination with other therapies for a better response. Here, the authors conduct a phase Ib clinical study and report the clinical activity and the immune response of the anti-PDL1 agent, atezolizumab, in combinat
Externí odkaz:
https://doaj.org/article/6805535216ff4aaca60ddedaf5252687
Autor:
Fabien Gaire, Neeraj Sharma, Xian He, James W. Mier, Genevive Hernandez, David F. McDermott, Mario Sznol, Konstanty Korski, Jeffrey Wallin, Roel Funke, Galina Babitski, Daniel Waterkamp, Priti S. Hegde, Vincent Leveque, Daniel S. Chen, Hartmut Koeppen, James Ziai, Johanna C. Bendell, Marta Cañamero, Mitchell Denker, F. Stephen Hodi, Suzanne F. Jones
Publikováno v:
Nature Communications
Nature Communications, Vol 7, Iss 1, Pp 1-8 (2016)
Nature Communications, Vol 7, Iss 1, Pp 1-8 (2016)
Anti-tumour immune activation by checkpoint inhibitors leads to durable responses in a variety of cancers, but combination approaches are required to extend this benefit beyond a subset of patients. In preclinical models tumour-derived VEGF limits im
Autor:
Zachary Boyd, Rin Nakamura, Gregg Fine, Thomas Powles, Priti S. Hegde, Xiaodong Shen, Daniel P. Petrylak, Nicholas J. Vogelzang, Daniel S. Chen, Teiko Sumiyoshi, Christina Rabe, Mitchell Denker, Marcin Kowanetz, Siew-leng Melinda Teng, Qun J Wu, Yuanyuan Xiao, Yohann Loriot
Publikováno v:
Journal for Immunotherapy of Cancer
Treatment options for metastatic urothelial bladder cancer (UBC) are limited. Mutational complexity is known to be high in UBC and may correlate with increased immunogenicity. MPDL3280A, a human PD-L1 monoclonal antibody containing an engineered Fc-d
Autor:
Eliezer M. Van Allen, Marcin Kowanetz, Priti S. Hegde, Joseph Kim, Nicholas J. Vogelzang, Charles G. Drake, Marcella Fassò, Sanjeev Mariathasan, Yohann Loriot, Mitchell Denker, Edward E. Kadel, Colombe Chappey, Thomas Powles, Joaquim Bellmunt, Zachary Boyd, Carol O'Hear, Wei Zou, Dorothee Nickles
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts Atezolizumab (anti-PD-L1) has demonstrated robust clinical activity in UBC [[1][1]]. Elevated PD-L1 expression on tumor-infiltrating immune cells (IC) is associated with increased clinical efficacy; however, the contribution of othe
Autor:
Marcin Kowanetz, Mitchell Denker, David R. Spigel, Hartmut Koeppen, Naiyer A. Rizvi, Mark M. Kockx, Priti S. Hegde, Alexandra Minn, David S. Shames, Daniel S. Chen, Alexander I. Spira, Edward E. Kadel, Ignacio I. Wistuba, Scott N. Gettinger, Fred R. Hirsch, Zachary Boyd, Alan Sandler
Publikováno v:
Journal of Clinical Oncology. 33:3015-3015
3015 Background: Programmed death ligand-1 (PD-L1) expression on tumor cells (TC) or tumor-infiltrating immune cells (IC) is associated with OS, PFS and ORR in patients with advanced NSCLC treated ...
Autor:
Xiaodong Shen, Daniel S. Chen, Gregg Fine, Marcin Kowanetz, Rin Nakamura, Rajesh Patel, Marigold Boe, Rupal Desai, Jean-Charles Soria, Cecilia Leddy, Roy S. Herbst, Jane Ruppel, Priti S. Hegde, Hartmut Koeppen, Mitchell Denker, John D. Powderly, Ahmad Mokatrin, Yuanyuan Xiao, Qun J Wu, Ling Fu, Christina Rabe, Holbrook E Kohrt, Teiko Sumiyoshi, Scott N. Gettinger
Publikováno v:
Journal for Immunotherapy of Cancer
PD-L1 expressed in the tumor microenvironment regulates Th1 immune responses and mediates cancer immune evasion through interactions with PD-1 or B7.1 receptors on activated T cells. MPDL3280A, an engineered human monoclonal antibody, targets PD-L1 a
Autor:
Hartmut Koeppen, Scott N. Gettinger, Marcin Kowanetz, Holbrook E Kohrt, Jenny Wu, Priti S. Hegde, D.S. Chen, MT Vu, Mitchell Denker, Cristina Cruz
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts PD-L1 regulates CD8 T cell/Th1 immune responses. PD-L1 expressed in the tumor microenvironment can bind to PD-1 or B7.1 on activated T cells and mediate cancer immune evasion. MPDL3280A is a human mAb containing an engineered Fc-dom